about
Brodalumab for the treatment of psoriasis.Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.Targeting IL-17 in psoriatic arthritis.Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Brodalumab: First Global Approval.
@en
type
label
Brodalumab: First Global Approval.
@en
prefLabel
Brodalumab: First Global Approval.
@en
P2860
P1433
P1476
Brodalumab: First Global Approval.
@en
P2093
Sarah L Greig
P2860
P2888
P304
P356
10.1007/S40265-016-0634-8
P577
2016-08-31T00:00:00Z
P6179
1009640884